Curve Biosciences Lands $40 Million

<p><strong>SAN MATEO<&sol;strong> &&num;8212&semi; <a href&equals;"https&colon;&sol;&sol;cts&period;businesswire&period;com&sol;ct&sol;CT&quest;id&equals;smartlink&amp&semi;url&equals;https&percnt;3A&percnt;2F&percnt;2Fwww&period;curvebio&period;com&percnt;2F&amp&semi;esheet&equals;54344930&amp&semi;newsitemid&equals;20251029166983&amp&semi;lan&equals;en-US&amp&semi;anchor&equals;Curve&plus;Biosciences&amp&semi;index&equals;1&amp&semi;md5&equals;0bf43aa552414d62ac706aadaf2c5d21" target&equals;"&lowbar;blank" rel&equals;"nofollow noopener" shape&equals;"rect">Curve Biosciences<&sol;a>&comma; a company developing a Whole-Body Intelligence perform to monitor diseases&comma; has raised &dollar;40 million in funding led by Luma Group with participation from First Spark Ventures&comma; Techas Capital&comma; Micah Spear&comma; Civilization Ventures&comma; LifeX Ventures&comma; Incite&comma; Mintaka VC&comma; NZVC&comma; and others&period;<&sol;p>&NewLine;<p>The funding will advance the clinical validation and commercialization of Curve’s Whole-Body Intelligence platform to transform chronic disease monitoring&period;<&sol;p>&NewLine;<p>Curve has created the first molecular blueprint of the human body with the company’s Whole-Body Atlas — the world’s largest collection of manually curated tissue samples characterized by organ and disease state&period; By returning to tissue-level biological truth&comma; the company is creating simple&comma; proactive Whole-Body Blood Tests that anticipate chronic disease&comma; guide treatment&comma; and align patients&comma; insurers&comma; pharma&comma; and doctors&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;Chronic diseases are on the rise&comma; and healthcare costs are skyrocketing as a result&period; We need to improve patient monitoring to realize the positive impacts of breakthroughs like GLP-1s&comma;” said Ritish Patnaik&comma; PhD&comma; CEO and Co-Founder&comma; Curve Biosciences&period; &OpenCurlyDoubleQuote;To raise the standard of chronic disease monitoring&comma; we are now introducing the first Whole-Body Intelligence platform with AI models trained on our Whole-Body Atlas and fueled by our Whole-Body Blood Tests&period; We’ve paired this platform with a successful executive team to realize our vision for proactive&comma; personalized chronic care that minimizes suffering&period;”<&sol;p>&NewLine;<p>Curve’s executive team includes&colon;<&sol;p>&NewLine;<ul class&equals;"bwlistdisc">&NewLine;<li>Ritish Patnaik&comma; PhD&comma; Chief Executive Officer – Former business development at Genentech&comma; with deep expertise in AI&comma; data engineering and precision testing&period;<&sol;li>&NewLine;<li>Nathan Hunkapiller&comma; PhD&comma; Chief Scientific Officer – Previously Head of R&amp&semi;D at Natera and Head of R&amp&semi;D at GRAIL&comma; where he led the development of advanced blood tests for oncology&comma; prenatal screening and hereditary cancer screening&period;<&sol;li>&NewLine;<li>Alice Chen&comma; PhD&comma; Chief Operating Officer – Former Head of Product and Program Management at GRAIL&comma; where she led strategy for a multi-cancer early detection blood test&comma; after leadership roles at Natera&comma; Progyny and Sienna Biopharmaceuticals&period;<&sol;li>&NewLine;<li>Chuba Oyolu&comma; PhD&comma; Chief Technology Officer – Founding Scientist and Senior Site Director at Counsyl&comma; where he led the automation&comma; delivery&comma; and scaling of advanced blood tests for prenatal screening and hereditary cancer screening&period;<&sol;li>&NewLine;<li>Prof&period; Shan Wang&comma; PhD&comma; Chief Innovation Officer and Scientific Founder – Leland T&period; Edwards Professor in the School of Engineering at Stanford University with 300&plus; publications and 70&plus; issued or pending patents over his 30&plus; year academic career&period;<&sol;li>&NewLine;<&sol;ul>&NewLine;<p>&OpenCurlyDoubleQuote;We believe Curve’s Whole-Body Intelligence platform represents the next frontier in clinical testing&comma; with the potential to fundamentally reshape how we monitor and manage chronic disease&comma;” said<b> <&sol;b>Themasap Khan&comma; PhD&comma; Co-Founder and Partner&comma; Luma Group&period; &OpenCurlyDoubleQuote;By anchoring in human tissue data&comma; Curve is building a clinically actionable platform with clear reimbursement potential and massive market applicability&period;”<&sol;p>&NewLine;

Editor

Deep Fission Uncovers $80 Million in Financing

BERKELEY -- Deep Fission, anadvanced nuclear energy company placing small modular pressurized water reactors (SMRs)…

2 days

Instacart Partners With 1-800-Flowers

SAN FRANCISCO and JERICHO, NY -- Instacart, the leading grocery delivery service, has signed its first nationwide…

2 days

Bretton AI Secures $75 Million

SAN FRANCISCO -- Bretton AI, formerly Greenlite AI, has secured a $75 million Series B funding…

2 days

Fundamental Emerges From Stealth With $255 Million

SAN FRANCISCO -- Fundamental, an AI company that has built its most powerful Large Tabular…

2 days

Turnstile Launches Quote-to-Cash Platform With $29 Million

SAN FRANCISCO -- Turnstile has launched a quote-to-cash platform for sales-led startups with $29 million in…

3 days

QuantumScape Reveals New Production Line

SAN JOSE -- QuantumScape Corporation, a developer of next-generation solid-state lithium-metal battery technology, celebrated the…

3 days